Real world cost of human epidermal receptor 2‐positive metastatic breast cancer patients: a longitudinal incidence‐based observational costing study in the Netherlands and Belgium

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2354|24|3|340-354

ISSN： 0961-5423

Source： EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol.24, Iss.3, 2015-05, pp. : 340-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 844-853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

By  

Case Reports in Oncology, Vol. 6, Iss. 3, 2013-09 ,pp. : 450-455

Karger

Access to resources Recommend Favorite

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3032-3040

John Wiley & Sons Inc

Access to resources Recommend Favorite